Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,258.44 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44. Following the transaction, the insider directly owned 1,057,231 shares of the company’s stock, valued at $10,593,454.62. The trade was a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

4D Molecular Therapeutics Stock Up 5.0%

NASDAQ FDMT opened at $10.01 on Friday. The company has a fifty day moving average of $9.56 and a two-hundred day moving average of $9.26. The firm has a market capitalization of $523.32 million, a price-to-earnings ratio of -3.89 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a 52 week low of $3.68 and a 52 week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current year.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. lifted its stake in 4D Molecular Therapeutics by 14,343.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 18,054 shares of the company’s stock worth $135,000 after acquiring an additional 17,929 shares during the period. Simplify Asset Management Inc. purchased a new stake in 4D Molecular Therapeutics in the first quarter worth about $656,000. Landing Point Financial Group LLC purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth about $142,000. AXQ Capital LP lifted its stake in 4D Molecular Therapeutics by 138.8% in the fourth quarter. AXQ Capital LP now owns 30,755 shares of the company’s stock worth $231,000 after acquiring an additional 17,876 shares during the period. Finally, Impact Partnership Wealth LLC lifted its stake in 4D Molecular Therapeutics by 36.5% in the fourth quarter. Impact Partnership Wealth LLC now owns 15,123 shares of the company’s stock worth $113,000 after acquiring an additional 4,045 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, May 8th. Chardan Capital reissued a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Finally, Royal Bank Of Canada boosted their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.